{
    "clinical_study": {
        "@rank": "87275", 
        "arm_group": {
            "arm_group_label": "Fluoxetine", 
            "arm_group_type": "Experimental", 
            "description": "Flexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and effectiveness of fluoxetine flexible dosing in the\n      treatment of MDD in adult Japanese participants.\n\n      Participants who complete the short-term treatment phase of Study B1Y-JE-HCLV (NCT#:\n      NCT01808612) will be allowed to enroll in this study, and receive fluoxetine treatment for\n      an additional 52 weeks."
        }, 
        "brief_title": "A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have completed Study B1Y-JE-HCLV (NCT#:NCT01808612)\n\n          -  Agree to abstain from sexual activity or to use a reliable method of birth control\n\n        Exclusion Criteria:\n\n          -  Significant suicidal risk\n\n          -  Have a current or previous diagnosis of bipolar disorder, psychotic depression,\n             schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive\n             disorder, or post-traumatic stress disorder\n\n          -  Have a history of substance abuse or dependence within the past 6 months, excluding\n             caffeine and nicotine\n\n          -  Need to use thioridazine or pimozide during the study\n\n          -  Have a positive urine drug screen for drugs with abuse potential\n\n          -  Female participants who are either pregnant, nursing, or have recently given birth,\n             or male participants who are planning for their partners to be or become pregnant\n\n          -  Have frequent or severe allergic reactions to multiple medications\n\n          -  Have a serious or unstable medical illness or condition, or psychological condition\n\n          -  Participants deemed ineligible by the investigator or sub-investigator for other\n             reasons"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808651", 
            "org_study_id": "14596", 
            "secondary_id": "B1Y-JE-HCLW"
        }, 
        "intervention": {
            "arm_group_label": "Fluoxetine", 
            "description": "Administered orally", 
            "intervention_name": "Fluoxetine", 
            "intervention_type": "Drug", 
            "other_name": [
                "LY110140", 
                "Fluoxetine Hydrochloride", 
                "Prozac", 
                "Sarafem"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Fluoxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan", 
                        "zip": "471-8513"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "270-0014"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "800-0226"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukushima", 
                        "country": "Japan", 
                        "zip": "963-877"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima", 
                        "country": "Japan", 
                        "zip": "737-0143"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "065-0012"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "651-0097"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan", 
                        "zip": "238-0042"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto", 
                        "country": "Japan", 
                        "zip": "616-8421"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagano", 
                        "country": "Japan", 
                        "zip": "390-0303"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama", 
                        "country": "Japan", 
                        "zip": "700-0907"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "586-0012"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan", 
                        "zip": "339-0057"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shiga", 
                        "country": "Japan", 
                        "zip": "525-0037"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan", 
                        "zip": "321-0953"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "170-0002"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3, Open-label, Long-Term Study to Evaluate the Safety of LY110140 Once Daily Dosing for 52-week in Japanese Patients With Major Depressive Disorder", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with Adverse Events (AEs) or Serious AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Week 52"
            }, 
            {
                "measure": "Number of Participants with Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Week 52"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808651"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Change from Baseline to Week 52 on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 52"
            }, 
            {
                "measure": "Percentage of Participants Achieving a Response at Week 52", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "Percentage of Participants Achieving a Remission at Week 52", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "Mean Change from Baseline to Week 52 on the Clinical Global Impression of Severity (CGI-S) Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 52"
            }, 
            {
                "measure": "Mean Change from Baseline to Week 52 on the HAMD21 Subscale Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 52"
            }, 
            {
                "measure": "Change from Baseline to Week 52 in Sheehan Disability Scale (SDS) Total Score and Subscale Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 52"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}